TELI CAP - Telithromycin in children with mild to moderate community-acquired pneumonia

Registry ID

EUCTR2014-002867-13

Source registry

EUCTR

Phase

PHASE3

Sponsor

Sanofi-aventis

Last update

2026-08-16

Conditions

• Community acquired pneumonia

Summary

To assess the steady state pharmacokinetics of telithromycin oral suspension (25 mg/kg once a day for 7-10 days), in children 6 months to less than 13 years of age (<13) with community acquired pneumonia (CAP).

Related clinical trials

• Influence of nasal highflow-therapy on oxygenation index compared with lowflowoxygen-therapy in patients with comunitiy aquired pneumonia on peripheral ward

View on source registry